Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psilocybin Drug Program for the Treatment of Pain and Eating Disorders Takes On Special Meaning Leading Up To The Holidays

  • People with eating disorders know all about the difficulties faced during holiday celebrations and their association with heavy eating
  • The fall-winter holiday season can also adversely affect people suffering from certain chronic pains, as temperatures and pressure changes can increase pain sensitivity
  • Tryp is looking to help alleviate problems associated with eating disorders and chronic pain through its psilocybin-based drug program that focuses on conditions with high unmet needs
  • The company has submitted several IND applications for Phase 2a studies evaluating TRP-8802’s effectiveness in patients with chronic pain and select eating disorders

There is no denying that food is a massive part of the holiday season. With this year’s Thanksgiving celebration kicking off the fall-winter holiday season that will stretch until New Year’s Day, Americans are likely to go all out foodwise, as is tradition. However, for people with eating disorders, the holiday season can constitute a major challenge.

“Holidays may trigger eating disordered behaviors and disordered eating due to the set of stressors that the holidays present; relationship stress, travel, finances, and holiday fatigue are the usual culprits,” explains Cecille Ahrens, a psychotherapist and addiction specialist (https://ibn.fm/kflMr).

Research suggests that stress pushes people living with eating disorders, including binge-eating disorder (“BED”), toward overeating as they seek to escape from reality and self-awareness. Unfortunately, this means that this year’s holiday season, as with all others before it, may exacerbate the situation among those suffering from eating disorders, causing them to eat even more.

At the same time, the fall-winter holiday season can also adversely impact those suffering from chronic pain. Winter, which comes with changes in temperature, pressure, and moisture, can cause chronic pain patients to experience more aches, stiffness, and a limited range of motion. According to the Pontchartrain Orthopedics & Sports Medicine organization, this heightened achiness considerably increases patients’ pain (https://ibn.fm/Yrp8X). The issue is further compounded by the fact that existing FDA-approved chronic pain drugs have limited efficacy and/or significant side effects.

Fortunately, positive change may be in the offing for people living with these conditions. Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company pursuing the development of novel bioscience solutions that aim to address indications with high unmet needs, is leading the next wave of psychedelic drug development with a laser focus on chronic pain, eating disorders, and other unique conditions.

The company has made significant progress as it advances toward the rollout of multiple Phase 2a clinical studies to be conducted in collaboration with the University of Michigan and the University of Florida. The studies will evaluate the safety and preliminary effectiveness of Tryp’s TRP-8802, a non-proprietary 25 mg oral capsule of synthetic psilocybin, for the treatment of fibromyalgia, phantom limb pain syndrome, complex regional pain syndrome, BED, and hypothalamic obesity.

In line with a recent response to its Investigational New Drug (“IND”) application, Tryp will focus enrollment of the initial Phase 2a study on patients with BED. In addition, the company will submit an IND application for a separate Phase 2a study evaluating TRP-8802 with hypothalamic obesity (https://ibn.fm/LvpL3).

Earlier in November, Tryp also submitted an IND application to evaluate the safety and preliminary effectiveness of TRP-8802 in a Phase 2a clinical trial involving patients with fibromyalgia, a class of chronic pain. Tryp anticipates initiating this study next year subject to a favorable review of the IND application (https://ibn.fm/tTavr).

Tryp has already received IND authorization for a Phase 2a clinical trial in phantom limb pain, a type of chronic pain (https://ibn.fm/YpmjK).

Tryp expects to use data from the multiple Phase 2a studies, as well as various data sets to support the use of TRP-8803, its proprietary psilocybin-based drug product with a novel route of administration, in Phase 2b studies. Eventually, the company intends to commercialize its drug product, potentially easing the challenges and difficulties that eating disorder patients and people suffering from chronic pain face during the holiday seasons.

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050